Advertisement
News
Subscribe to MDT Magazine News

New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations

December 9, 2010 5:32 am | by Bio-Medicine.Org | Comments

RIDGEFIELD, Conn., Dec. 9, 2010 /- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free...

TOPICS:

Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity

December 9, 2010 5:31 am | by Bio-Medicine.Org | Comments

ATLANTA, Dec. 9, 2010 /- Customers using Elekta's MOSAIQ® oncology information system (OIS) experience success with seamless integration to Varian's TrueBeam ™ system for radiation therapy delivery. The MOSAIQ interface to this linear accelerator is the most recent example of...

TOPICS:

Study: Half of women over 40 get annual mammograms

December 9, 2010 4:46 am | by MARILYNN MARCHIONE - AP Medical Writer - Associated Press | Comments

Many people disagreed when a government task force said that most women don't need annual mammograms. But new research shows that only half of women over 40 had been getting them that often to start with.A review of insurance claims on more than 1.5 million women finds that among those 40 to 85...

Advertisement

States Now Fund Majority of Human Embryonic Stem Cell Research

December 9, 2010 4:33 am | by Georgia Tech Institute of Technology | Comments

States, not the federal government, now fund the majority of human embryonic stem cell research conducted in the United States, according to a study by Aaron Levine in the journal Nature Biotechnology.  In addition, much of the research performed in the states could likely have been...

Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test

December 9, 2010 3:35 am | by Bio-Medicine.Org | Comments

ALISO VIEJO, Calif., Dec. 9, 2010 /- Clarient, Inc. (Nasdaq: CLRT ), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the...

TOPICS:

Docs show Calif.'s worldwide execution drug search

December 9, 2010 1:45 am | by PAUL ELIAS - Associated Press - Associated Press | Comments

The e-mail from one California prison official to another almost reads like something out of a spy novel: "May have a secret and important mission for you."Department of Corrections and Rehabilitation undersecretary Scott Kernan sent that message to assistant secretary Anthony Chaus on Sept....

APNewsBreak: Calif. scrambled for execution drug

December 8, 2010 10:45 pm | by PAUL ELIAS - Associated Press - Associated Press | Comments

California prison officials went on a frantic two-month search for a lethal drug needed to carry out the state's first execution in five years, which ultimately was called off, documents released late Wednesday showed.The officials traded lethal injection drugs with their counterparts in...

Study examines effect of water-based and silicon-based lubricant

December 8, 2010 9:35 pm | by EurekAlert | Comments

(Indiana University) A new study by sexual health researchers at Indiana University found that women who used lubricant during sex reported significantly higher levels of satisfaction and pleasure. The study, involving 2,453 women, is the largest systematic study of this kind,...

TOPICS:
Advertisement

Assured Pharmacy, Inc. Receives Gross Proceeds of $300,000 from Sale of Convertible Debentures and Warrants

December 8, 2010 3:39 pm | by Bio-Medicine.Org | Comments

FRISCO, Texas, Dec. 8, 2010 /- Assured Pharmacy, Inc. (Pink Sheets: APHY ) (the "Company"), a growing chain of specialty pharmacies that provides advanced prescription services to a diverse array of medical professionals and their patients, announced today that it sold in a private...

TOPICS:

Amgen to Present at Deutsche Bank's 2010 BioFEST

December 8, 2010 3:39 pm | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif., Dec. 8, 2010 /- Amgen (Nasdaq: AMGN ) will participate in Deutsche Bank's 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development and Arvind Sood,...

TOPICS:

Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism

December 8, 2010 3:39 pm | by Bio-Medicine.Org | Comments

EMERYVILLE, Calif., Dec. 8, 2010 /- Bionovo, Inc. (Nasdaq: BNVI ) today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that...

TOPICS:

Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis

December 8, 2010 3:38 pm | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 8, 2010 /- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the execution of an oncology-focused mutational analysis services agreement with Bayer Schering Pharma AG, Germany, a worldwide leading pharmaceutical company. The...

TOPICS:

Netsmart Technologies is First Behavioral Healthcare Software Provider to Attain Complete ARRA-Certified Electronic Health Record

December 8, 2010 3:38 pm | by Bio-Medicine.Org | Comments

GREAT RIVER, N.Y., Dec. 8, 2010 /- Netsmart Technologies, Inc., a leading provider of software and services for health and human services organizations, today announced that its Avatar™ 2011 electronic health record (EHR) software has achieved 100 percent ONC-ATCB ARRA ambulatory...

TOPICS:

New York Robotic Surgery Expert Dr. David Samadi, MD Discusses New Findings that Hormone Therapy May Increase Risk of Developing Colorectal Cancer(2)

December 8, 2010 3:37 pm | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 8, 2010 /- Androgen deprivation therapy has often been prescribed as a prostate cancer treatment for low-risk prostate cancer patients. This therapy for treating prostate cancer had previously been blamed for increased risk of cardiovascular disease and heart conditions....

TOPICS:

Streamline Health Solutions Reports Q3 Results

December 8, 2010 3:37 pm | by Bio-Medicine.Org | Comments

CINCINNATI, Dec. 8, 2010 /- Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced financial results for the third quarter of fiscal year 2010, ended October 31, 2010. Highlights for the quarter included: Revenue for the quarter increased 9% over prior year's comparable...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading